2. Results and Discussion
2.1. Antimony as an Occupational Hazard
2.1.1. Inhalational Exposure
188.8.131.52. Respiratory Effects
184.108.40.206. Cardiovascular Effects
220.127.116.11. Gastrointestinal Effects
18.104.22.168. Dermal effects
22.214.171.124. Reproductive Effects
2.1.2. Oral Exposure
2.1.3. Other Exposure from Antimony Compounds
2.1.4. Prevention of Exposure to Antimony
2.2. Antimony in Therapeutics
- Agency for Toxic Substances and Disease Registry. ToxFAQs™ for Antimony and Compounds. Available online: http://www.atsdr.cdc.gov/tfacts23.html (accessed on 28 January 2010).
- Summary of Guidelines for Canadian Drinking Water Quality. Available online: http://www.health.gov.sk.ca/water-guidelines-water-quality (accessed on 21 February 2010).
- Summaries & Evaluations Antimony Trioxide and Antimony Trisulfide; International Agency for Research on Cancer: Lyon, France, 1989. Available online: http://www.inchem.org/documents/iarc/vol47/47-11.html (accessed on 29 January 2010).
- McCallum, RI. Antimony in Medical History; The Pentland Press: Edinburgh, UK, 1999. [Google Scholar]
- Toxicological Profile for Antimony; US Agency for Toxic Substances and Disease Registry: Atlanta, GA, USA. Available online: http://www.atsdr.cdc.gov/toxprofiles/tp23.html (accessed on 29 January 2010).
- Iyengar, GV; Tanner, JT; Wolf, WR; Zeisler, R. Preparation of a mixed human diet material for the determination of nutrient elements, selected toxic elements and organic nutrients: A preliminary report. Sci. Total Environ 1987, 61, 235–252. [Google Scholar]
- Thomas, RG; Felicetti, SW; Lucchino, RV; McClellan, RO. Retention patterns of antimony in mice following inhalation of particles formed at different temperatures. Proc. Exp. Biol. Med 1973, 144, 544–550. [Google Scholar]
- Felicetti, SW; Thomas, RG; McClellan, RO. Retention of inhaled antimony-124 in the beagle dog as a function of temperature of aerosol formation. Health Phys 1974, 26, 525–531. [Google Scholar]
- Cooper, DA; Pendergrass, EP; Vorwald, AJ; Mayock, RL; Brieger, H. Pneumoconiosis among workers in an antimony industry. Am. J. Roentgen. Rad. Ther. Nuclear Med 1968, 103, 495–508. [Google Scholar]
- Potkonjak, V; Pavlovich, M. Antimoniosis: A particular form of pneumoconiosis. I. Etiology, clinical and x-ray findings. Int. Arch. Occup. Environ. Health 1983, 51, 199–207. [Google Scholar]
- Karajovic, D. Pneumokoniosen bei arbeitern einer antimonhutte. Proceedings of the 12th Congress of Occupational Health; 1958; pp. 370–374, (Cited in Public Health Goal for Antimony in Drinking Water; Prepared by Pesticide and Environmental Toxicology Section Office of Environmental Health Hazard Assessment California Environmental Protection Agency December 1997). [Google Scholar]
- Gross, P; Westrick, ML; Brown, JH; Srsic, RP; Schrenk, HH; Hatch, TF. Toxicologic study of calcium halophosphate phosphors and antimony trioxide. II. Pulmonary studies. AMA Arch. Ind. Health 1955, 11, 479–486. [Google Scholar]
- Brieger, H; Semisch, CW, 3rd; Stasney, J; Piatnek, DA. Industrial antimony poisoning. Ind. Med. Surg 1954, 23, 521–523. [Google Scholar]
- Taylor, PJ. Acute intoxication from antimony trichloride. Br. J. Ind. Med 1966, 23, 318–321. [Google Scholar]
- Renes, LE. Antimony poisoning in industry. Arch. Ind. Hyg 1953, 7, 99–108. [Google Scholar]
- Stevenson, CJ. Antimony spots. Trans. St. Johns Hosp. Dermatol. Soc 1965, 51, 40–42. [Google Scholar]
- White, GP, Jr; Mathias, CG; Davin, JS. Dermatitis in workers exposed to antimony in a melting process. J. Occup. Med 1993, 35, 392–395. [Google Scholar]
- Belyaeva, AP. The effect of antimony on reproduction. Gig. Truda. Prof. Zabol 1967, 11, 32. [Google Scholar]
- Paton, GR; Allison, AC. Chromosome damage in human cell cultures induced by metal salts. Mutat. Res 1972, 16, 332–336. [Google Scholar]
- Cavallo, D; Iavicoli, I; Setini, A; Marinaccio, A; Perniconi, B; Carelli, G; Iavicoli, S. Genotoxic risk and oxidative DNA damage in workers exposed to antimony trioxide. Environ. Mol. Mutagen 2002, 40, 184–189. [Google Scholar]
- Asakura, K; Satoh, H; Chiba, M; Okamoto, M; Serizawa, K; Nakano, M; Omae, K. Genotoxicity studies of heavy metals: Lead, Bismuth, Indium, Silver and Antimony. J. Occup. Health 2009, 51, 498–512. [Google Scholar]
- Dunn, JT. A curious case of antimony poisoning. Analyst 1928, 531, 532–533. [Google Scholar]
- Richardson, BA. Cot mattress biodeterioration and SIDS. Lancet 1990, 335, 670. [Google Scholar]
- Cullen, A; Kiberd, B; Devaney, D; Gillan, J; Kelehan, P; Matthews, TG; Mayne, P; Murphy, N; O’Regan, M; Shannon, W; Thornton, L. Concentrations of antimony in infants dying from SIDS and infants dying from other causes. Arch. Dis. Child 2000, 82, 244–247. [Google Scholar]
- De Perio, MA; Durgam, S; Caldwell, KL; Eisenberg, J. A health hazard evaluation of antimony exposure in fire fighters. J. Occup. Environ. Med 2010, 52, 81–84. [Google Scholar]
- Niosh Safety and Health Topic: Fire Fighter Fatality Investigation and Prevention Program. Available online: http://www.cdc.gov/niosh/fire/spotlight.html (accessed on 28 January 2010).
- National Primary Drinking Water Regulations Antimony, EPA 811-F-95-002j-T; Office of Water, US Environmental Protection Agency: Washington, DC, USA, 1995.
- Antimony in Drinking-Water Background Document for Development of WHO Guidelines for Drinking-Water Quality; World Health Organization: Geneva, Schwitzerland, 2003. Available online: http://www.who.int/water_sanitation_health/dwq/chemicals/antimony.pdf (accessed on 29 January 2010).
- Sneader, W. Drug Discovery: A History; John Wiley & Sons: West Susssex, UK, 2005; pp. 57–59. [Google Scholar]
- Farid, Z; Bassily, S; Kent, DC; Hassan, A; Abdel-Wahab, MF; Wissa, J. Urinary schistosomiasis treated with sodium antimony tartrate a quantitative evaluation. Brit. Med. J 1968, 3, 713–714. [Google Scholar]
- Davis, A. Comparative trials of antimonial drugs on urinary schistosomiasis. Bull. World Health Organ 1968, 38, 197–227. [Google Scholar]
- Cook, GC. Leishmaniasis: some recent developments in chemotherapy. J. Antimicrob. Chemother 1993, 31, 327–330. [Google Scholar]
- Conquest of kala-azar. Science and Culture 1941, VI, 528–534.
- Herwaldt, BL; Berman, JD. Recommendations for treating leishmaniasis with sodium stibogluconate (Pentostam) and review of pertinent clinical studies. Am. J. Trop. Med. Hyg 1992, 46, 296–306. [Google Scholar]
- Navin, TR; Arana, BA; Arana, FE; Berman, JD; Chajón, JF. Placebo-controlled clinical trial of sodium stibogluconate (Pentostam) versus ketoconazole for treating cutaneous leishmaniasis in Guatemala. J. Infect. Dis 1992, 165, 528–534. [Google Scholar]
- Chulay, JD; Spencer, HC; Mugambi, M. Electrocardiographic changes during treatment of leishmaniasis with pentavalent antimony (sodium stibogluconate). Am. J. Trop. Med. Hyg 1985, 34, 792–799. [Google Scholar]
- Sundar, S; Singh, VP; Sharma, S; Makharia, MK; Murray, HW. Response to interferon-g plus antimony in Indian visceral leishmaniasis. J. Infect. Dis 1997, 176, 1117–1119. [Google Scholar]
- Singh, NKP; Sharma, D; Jha, TK. Kala-azar mortality in hospitalized cases in North Bihar, India. J. Assoc. Physicians India 1989, 37, 514–516. [Google Scholar]
- Fisch, C. Braunwald, E, Ed.; Electrocardiography and vectorcardiography. In Heart Diseases, 2nd ed; W. B. Saunders Co: Philadelphia, PA, USA, 1984; pp. 195–257. [Google Scholar]
- Sundar, S; Sinha, PR; Agrawal, NK; Srivastava, R; Rainey, PM; Berman, JD; Murray, HW; Singh, VP. A cluster of cases of severe cardiotoxicity among Kala-Azar patients treated with a high-osmolarity lot of sodium antimony gluconate. Am. J. Trop. Med. Hyg 1998, 59, 139–143. [Google Scholar]
- Rijal, S; Chappuis, F; Singh, R; Boelaert, M; Loutan, L; Koirala, S. Sodium stibogluconate cardiotoxicity and safety of generics. Trans. R. Soc. Trop. Med. Hyg 2003, 97, 597–598. [Google Scholar]
- Kuryshev, YA; Wang, L; Wible, BA; Wan, X; Ficker, E. Antimony-based antileishmanial compounds prolong the cardiac action potential by an increase in cardiac calcium currents. Mol. Pharmacol 2006, 69, 1216–1225. [Google Scholar]
- Croft, SL; Sundar, S; Fairlamb, AH. Drug Resistance in Leishmaniasis. Clin. Microbiol. Rev 2006, 19, 111–126. [Google Scholar]
- Miller, WH, Jr; Schipper, HM; Lee, JS; Singer, J; Waxman, S. Mechanism of action of arsenic trioxide. Cancer Res 2002, 62, 3893–3903. [Google Scholar]
- Delgado, J; Macías, J; Pineda, JA; Corzo, JE; González-Moreno, MP; De la Rosa, R; Sánchez-Quijano, A; Leal, M; Lissen, E. High frequency of serious side effects from meglumine antimoniate given without an upper limit dose for the treatment of visceral leishmaniasis in human immunodeficiency virus type 1-infected patients. Am. J. Trop. Med. Hyg 1999, 61, 766–769. [Google Scholar]
- Franco, MA; Barbosa, AC; Rath, S; Dorea, JG. Antimony oxidation states in antileishmanial drugs. Am. J. Trop. Med. Hyg 1995, 52, 435–437. [Google Scholar]
- Murthy, UK; DeGregorio, F; Oates, RP. Hyperamylasemia in patients with the acquired immunodeficiency syndrome. Am. J. Gastroenterol 1992, 87, 332–336. [Google Scholar]
- Cappell, MS. The pancreas in AIDS. Gastroenterol. Clin. North Am 1997, 26, 337–365. [Google Scholar]
- Soto, J; Valda-Rodriquez, L; Toledo, J; Vera-Navarro, L; Luz, M; Monasterios-Torrico, H; Vega, J; Berman, J. Comparison of generic to branded pentavalent antimony for treatment of new world cutaneous leishmaniasis. Am. J. Trop. Med. Hyg 2004, 71, 577–581. [Google Scholar]
- Romero, GA; Flores, MRM; Noronha, EF; Macêdo Vde, O. High frequency of skin reactions in patients with leishmaniasis treated with meglumine antimoniate contaminated with heavy metals: a comparative approach using historical controls. Mem. Inst. Oswaldo. Cruz 2003, 98, 145–149. [Google Scholar]
- Olliaro, P; Sundar, S. Anthropometrically derived dosing and drug costing calculations for treating visceral leishmaniasis in Bihar, India. Trop. Med. Int. Health 2009, 14, 88–92. [Google Scholar]
- Seaman, J; Pryce, D; Sondorp, HE; Moody, A; Bryceson, AD; Davidson, RN. Epidemic visceral leishmaniasis in Sudan: a randomized trial of aminosidine plus sodium stibogluconate versus sodium stibogluconate alone. J. Infect. Dis 1993, 168, 715–720. [Google Scholar]
- Chunge, CN; Owate, J; Pamba, HO. Treatment of visceral leishmaniasisin Kenya by aminosidine alone or combined with sodium stibogluconate. Trans. R. Soc. Trop. Med. Hyg 1990, 84, 221–225. [Google Scholar]
- Thakur, CP; Olliaro, P; Gothoskar, S; Bhowmick, S; Choudhury, BK; Prasad, S; Kumar, M; Verma, BB. Treatment of visceral leishmaniasis (kala-azar) with aminosidine (=paromomycin)-antimonial combinations, a pilot study in Bihar, India. Trans. R. Soc. Trop. Med. Hyg 1992, 86, 615–616. [Google Scholar]
- Melaku, Y; Collin, SM; Keus, K; Gatluak, F; Ritmeijer, K; Davidson, RN. Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium stibogluconate combined with paromomycin: a retrospective comparison with 30-day sodium stibogluconate monotherapy. Am. J. Trop. Med. Hyg 2007, 77, 89–94. [Google Scholar]
© 2010 by the authors; licensee Molecular Diversity Preservation International, Basel, Switzerland. This article is an open-access article distributed under the terms and conditions of the Creative Commons Attribution license (http://creativecommons.org/licenses/by/3.0/).
Share and Cite
Sundar, S.; Chakravarty, J. Antimony Toxicity. Int. J. Environ. Res. Public Health 2010, 7, 4267-4277. https://doi.org/10.3390/ijerph7124267
Sundar S, Chakravarty J. Antimony Toxicity. International Journal of Environmental Research and Public Health. 2010; 7(12):4267-4277. https://doi.org/10.3390/ijerph7124267Chicago/Turabian Style
Sundar, Shyam, and Jaya Chakravarty. 2010. "Antimony Toxicity" International Journal of Environmental Research and Public Health 7, no. 12: 4267-4277. https://doi.org/10.3390/ijerph7124267